Competition between co-occurring invasive and native consumers switches between habitats by Zwerschke, Nadescha et al.
Competition between co-occurring invasive and native consumers
switches between habitats
Zwerschke, N., van Rein, H., Harrod, C., Reddin, C., Emmerson, M., Roberts, D., & O'Connor, N. (2018).
Competition between co-occurring invasive and native consumers switches between habitats. Functional
Ecology, 1-13. DOI: 10.1111/1365-2435.13211
Published in:
Functional Ecology
Document Version:
Publisher's PDF, also known as Version of record
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
Copyright 2018 the authors.
This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/),
which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:10. Nov. 2018
Article
Development of a core outcome set
for trials investigating the long-term
management of bronchiectasis
Maureen Spargo1 , Cristı´n Ryan2,
Damian Downey3,4 and Carmel Hughes1
Abstract
Heterogeneity in outcomes measured in trials limits accurate comparison of bronchiectasis studies. A core
outcome set (COS) is an agreed, standardized set of outcomes that should be measured in trials for specific
clinical areas. A COS for bronchiectasis could encourage consistency in future studies. An overview of
systematic reviews and qualitative study on outcome selection in bronchiectasis informed an initial list of
outcomes. A Delphi panel (n ¼ 86) rated the importance of each outcome from 1 to 9 in 3 sequential
questionnaires, as a means to achieve consensus: 1–3 ¼ ‘of limited importance’; 4–6 ¼ ‘important, but not
critical’; and 7–9 ¼ ‘critical’. Outcomes rated ‘critical’ by 70% of the panel were added to the COS. Eighty-
two participants responded to the first questionnaire. Attrition between each questionnaire was 5%. After 3
rounds of questioning, 18 outcomes exceeded the threshold for consensus and were included in the COS. This
study has achieved consensus on 18 outcomes that should be measured in trials of interventions for
bronchiectasis. Selection of the highest ranked outcomes may represent a pragmatic means for comparison.
Further research is required to condense the number of outcomes selected and to determine its relevance to
interventions.
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Background
Recent developments in bronchiectasis research have
been attributable to an increased interest and invest-
ment into the condition.1 Although there are currently
no licensed therapies for bronchiectasis, randomized
controlled trials (RCTs) investigating the manage-
ment of the condition are under way.1 Systematic
review and meta-analysis to synthesize the results of
emerging RCT data will follow. However, meta-
analysis between similar interventions is often not
possible or limited because there is marked variability
in the outcomes that are measured and reported by
researchers. For example, meta-analysis was limited
in a 2015 Cochrane systematic review of prolonged
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antibiotics for bronchiectasis because of the diversity
of outcomes reported in the included trials.2 Hetero-
geneity between studies makes it difficult to com-
pare the effectiveness of two interventions when
they have been investigated in different ways.3 It
also limits the extent to which the data can be used
to inform clinical guidelines.4
A new approach in research methodology that is
gaining recognition in the scientific literature is the
development and implementation of a core outcome
set (COS).3 This approach seeks to overcome the
challenges presented by heterogeneity between stud-
ies. A COS is defined as an agreed, standardized set of
outcomes that should be measured and reported as a
minimum in all clinical trials for a specific clinical
area.3 The aim in the development of a COS is to
reach consensus on ‘what’ outcomes should be mea-
sured and reported, rather than ‘how’ or ‘when’ such
outcomes should be measured.3 The Core Outcome
Measures in Effectiveness Trials (COMET) Hand-
book was published in June 2017 (i.e. after the present
study had been undertaken) and recommends a four-
step process to COS development (Figure 1).5
A COS for bronchiectasis could ensure consistency
in future clinical trials designed to test the effective-
ness of new and existing management strategies for
the condition. It would allow for better comparison
between studies and ensure only the most effective,
rigorously tested strategies are recommended for
patients.6 The study described in this article aimed
to develop a COS for the long-term management of
bronchiectasis in adults.
Methods
Definitive guidance on COS development was una-
vailable at the time this study was conducted. There-
fore, an approach detailed in a discussion paper by
Williamson et al.,3 which preceded the COMET
Handbook (version 1.0), was followed.5 The method
used closely aligns with the four steps illustrated in
Figure 1 and differs only by the omission of a face-to-
face meeting to discuss the final COS, which had been
previously recommended to be an optional step in
COS development.3
The scope of the intended COS was defined to
include all interventions for the long-term manage-
ment of bronchiectasis in adults. Both pharmacologi-
cal and non-pharmacological interventions were
included in the scope to provide a COS that, if imple-
mented in all trials, could help clinicians directly
compare a wide range of strategies and inform recom-
mendations about those most suitable for patients
with different preferences and needs.
The COMET database was searched using the
keywords ‘Bronchiectasis’ and ‘Lungs & airways’
in February 2016 and did not identify COS studies
of relevance. For the purposes of this study, the term
Figure 1. Four-step process to the development of a COS (adapted from the COMET Handbook (version 1.0).5
COS: core outcome set; COMET: Core Outcome Measures in Effectiveness Trials; COS-STAR: Core Outcome
Set-STAndards for reporting.
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‘outcome’ was defined as a consequence of bronch-
iectasis that is experienced directly by the patient. It is
distinct from the terms ‘marker’, ‘measure’ or ‘out-
come measure’, which refer to the measurements or
instruments known to be associated with outcomes.7,8
The study was prospectively registered on the
COMET database (registration number 936; http://
www.comet-initiative.org/studies/details/936). A pro-
tocol was developed that established a plan for iden-
tifying the outcomes that should be included in a COS
for bronchiectasis. This involved (1) a review of exist-
ing knowledge on outcomes selection in bronchiecta-
sis9 and (2) a consensus study to gather opinions of
key stakeholders in bronchiectasis.10 These publica-
tions were used as they represented the most recent
publications at the time this study was conducted in
terms of synthesis of evidence9 and consultation with
key stakeholders, including health care professionals
and patients.
Review of existing knowledge
A review of outcomes selection for bronchiectasis
trials was conducted as part of an overview of inter-
ventions included in Cochrane systematic reviews
for the treatment of bronchiectasis.9 Outcomes that
had been measured in previous trials were summar-
ized to ‘inform a set of standard outcomes for future
research studies’.9
In 2014, a consultation with key stakeholders in the
management of bronchiectasis was conducted as part
of a study to develop an adherence intervention for
bronchiectasis.10 Researchers in Belfast, Northern
Ireland, facilitated a series of three expert panels
attended by patients (n ¼ 11), health care profession-
als and academics (n¼ 9) from different backgrounds
(bronchiectasis management, intervention develop-
ment, commissioning of services and adherence
research).10 Panel members were asked, among other
topics, to discuss their views on how the intervention
could be evaluated, specifically what outcomes the
study should measure.10
Together these studies provided a convenient start-
ing point for the development of a COS for bronch-
iectasis. Outcomes within the scope of the COS were
extracted from both studies and compiled into a long-
list of potential outcomes for consideration for inclu-
sion in the COS (see Online Supplemental Material).
Items that were outside the scope of the COS and
those considered to be measures or markers of an
outcome were excluded. Duplicates were removed
and terminology standardized.
Consensus exercise
The Delphi technique has been proposed as the suit-
able method of reaching consensus when developing a
COS and was the approach taken for this study.5,11
Participants for the Delphi panel were recruited from
the European Multicentre Bronchiectasis Audit and
Research Collaboration (EMBARC) network and
from a patient advisory group coordinated by the Eur-
opean Lung Foundation. A pragmatic target sample
size of at least 100 participants consisting of at least
40 secondary care physicians, 12 physiotherapists,
12 nurses and 35 patient representatives was set. A
higher proportion of physicians to others was chosen
to reflect the higher proportion of physicians who are
involved with bronchiectasis research. With an antici-
pated response rate of 70–75%, a minimum of 140 (at
least 55 physicians, 15 physiotherapists, 15 nurses and
50 patient representatives) invitees were required.
This response rate was based on a modified Delphi
study, which achieved a 72% response rate to ques-
tionnaires sent to 138 EMBARC members.12
In response to slow recruitment of nurses and phy-
siotherapists, the protocol was amended to invite con-
tacts known to the research team and to ask recruited
participants to refer nurse and physiotherapists who
would be interested in taking part. Those who had
proven direct involvement with the care of people
with bronchiectasis, or in bronchiectasis research,
were invited to take part.
The views of participants on outcomes that should
be included in the COS were gathered using a series
of three consecutive Delphi questionnaires dis-
tributed by email, with a Web-based survey tool
(SurveyGizmo®). Participants were asked to complete
the questionnaire within 3 weeks; non-respondents
were sent a reminder email 2 weeks later. Only par-
ticipants who responded to the first questionnaire
were invited to participate in the second round of
questioning, and likewise, only participants who
responded to the second questionnaire were invited
to complete the third questionnaire. Questionnaires
were piloted by a COS developer at Queen’s Univer-
sity Belfast who was not connected with the current
study to ensure that there were no technical difficul-
ties and that questions were in a logical sequence.
In the first questionnaire, participants were pre-
sented with an initial list of outcomes (Table 1),
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derived from the review of existing knowledge.9,10
These were accompanied by plain language explana-
tions where required. Participants were instructed to
rate the relative importance of each outcome. The
Grading of Recommendations Assessment, Develop-
ment and Evaluation (GRADE) Working Group scale
was used to help participants consider the relative
importance of each outcome in the list and was used
to determine when consensus had been achieved (see
Table 2).3,13 A screenshot of part of the online ques-
tionnaire is provided in Figure 2.
In the first questionnaire, participants also had the
opportunity to suggest outcomes they believed should
be included. The appropriateness of outcomes pro-
posed by participants was reviewed and discussed
by the study group. An outcome was defined as
‘appropriate’ if it represented a new and distinct out-
come and was not considered to be a subset of any
existing outcome. Outcomes that had been suggested
by participants that were deemed appropriate by the
study group were included in the second questionnaire
and are shown in Figure 3.3
In the second questionnaire, participants were pre-
sented with a revised list of outcomes comprising the
original list and any new outcomes yielded from the
first questionnaire. Feedback about how the panel had
collectively rated each outcome in the first question-
naire was displayed under each outcome. Participants
were also sent a summary about how they had per-
sonally rated each outcome. This allowed participants
to reflect on their own responses in relation to the
collective response of the panel before rating the out-
come again.
In the third questionnaire, participants were pre-
sented with a list of outcomes for which consensus
had not been reached and asked to rate them again
using the same scoring system as before. Similar to
the second round, participants received individual and
group feedback on how each outcome was scored.
Suggestions for additional outcomes were not col-
lected in the second or third questionnaires.
After each round of questioning, the percentage of
participants who rated each outcome in terms of
importance was determined. Consensus ‘in’, that is,
the outcome should be included in the COS, was con-
firmed, if after the second or third round of question-
ing, 70% or more of participants rated an outcome 7 to
9, that is ‘Critical’ and fewer than 15% of participants
rated it 1 to 3, that is ‘Of limited importance’.13 The
same thresholds have been used in the development of
COS in other clinical conditions.14,15
The Core Outcome Set-STAndards for Reporting
(COS-STAR) guidelines have been used to report the
findings of this study, and a completed checklist is
provided in the Online Supplemental Material.16
Ethics approval and consent to participate
A proportionate review subcommittee of the London
– Camden & King’s Cross Research Ethics Commit-
tee gave the study a favourable ethical opinion on 13
September 2016 regarding the involvement of patient
Table 1. Outcomes presented in first questionnaire.
Outcome
Lung function
Pulmonary exacerbations
Shortness of breath
Wheeze
Cough
Exercise tolerance
Sputum characteristics
Death (all-cause)
Death (disease)
Quality of life
Patient perception of health
Patient perception of mood
Ability to work
Adherence to intervention
Admissions to hospital
Diarrhoea
Rash
Shortness of breath
Wheeze
Serious adverse events
Table 2. GRADE Working Group scale3,13 for rating the
importance of outcomes.
Rating Interpretation
1
Outcome is ‘Of limited importance’ and should
not be included in the COS
2
3
4
Outcome is ‘Important, but not critical’ and
should not be included in the COS
5
6
7
Outcome is ‘Critical’ and should be included in
the COS
8
9
Unable
to rate
Participant unable to rate the outcome
GRADE: Grading of Recommendations Assessment, Develop-
ment and Evaluation; COS: core outcome set.
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Figure 2. Screenshot of part of questionnaire 1.
Figure 3. Outcome selection and progression through three Delphi questionnaires.
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representatives from the United Kingdom (UK; refer-
ence number 16/LO/1712). The School of Pharmacy
Ethics Committee at Queen’s University Belfast
(QUB) also reviewed the study with regard to the
involvement of health professionals and non-UK
patient representatives and granted its approval on 5
September 2016 (reference number 018PMY2016).
Permission to implement an amendment was granted
by the QUB School of Pharmacy Ethics Committee
on 3 November 2016.
Results
An initial list of 20 outcomes was compiled from
those specified by Welsh et al.9 and suggested by the
bronchiectasis stakeholder panels (see Table 1 and
Figure 3).10 All outcomes suggested by Welsh et al.
were included (n ¼ 15).9 Outcomes that had been
listed separately according to how they were mea-
sured were included as one outcome. For example,
‘exacerbations per year’ and ‘time to first exacerba-
tion’ were listed singularly as ‘Exacerbations’. Nine
outcomes were suggested in the McCullough study,
four overlapped with those identified by Welsh et al.,
yielding an additional five outcomes for consideration
by the Delphi panel, resulting in a final list of
20 outcomes.9,10
A total of 180 individuals were invited to partici-
pate in the Delphi panel: 70 doctors, 60 allied health
professionals (AHPs), including nurses and
physiotherapists and 50 patient representatives.
Eighty-six participants were successfully recruited
to the study (recruitment rate 48%). The respective
recruitment rates for doctors, AHPs and patient rep-
resentatives were 64% (n ¼ 45), 30% (n ¼ 18) and
46% (n ¼ 23), respectively. Twenty-two European
countries were represented. Participants covered 22
European countries; most participants (n ¼ 42,
51%) lived or worked in the United Kingdom, with
the second largest cohort living or working in Spain (n
¼ 7, 9%). Four participants did not respond to the first
questionnaire (response rate ¼ 95%). There was a 5%
attrition rate between each subsequent round of ques-
tioning. The numbers and characteristics of partici-
pants who responded to the questionnaires at each
of the three rounds of questioning are provided in
Table 3.
As planned and regardless of how they were rated,
all 20 outcomes proceeded to the second round of
questioning. An additional 12 outcomes that had been
suggested by participants and deemed appropriate by
Table 3. Characteristics of respondents to Delphi questionnaires.
Characteristics
Participants, n (%)
Questionnaire 1 Questionnaire 2 Questionnaire 3
Total respondents 82 (95.3) 78 (95.1) 74 (94.8)
Gender
Female 53 (64.6) 50 (64.1) 47 (63.5)
Male 29 (35.4) 28 (35.9) 27 (36.5)
Role
Doctor 42 (51.2) 40 (51.3) 38 (51.4)
Physiotherapist 10 (12.2) 10 (12.8) 10 (13.5)
Nurse 8 (9.8) 7 (9.0) 6 (8.1)
Patient representative 22 (26.8) 21 (26.9) 20 (27.0)
Research involvement
Lead investigator 29 (35.4) 27 (34.6) 27 (36.5)
Member of a research team 18 (22) 17 (21.8) 16 (21.6)
Involved with funding research 1 (1.2) 1 (1.3) 1 (1.4)
Participant in research 12 (14.6) 12 (15.4) 11 (14.9)
Not previously involved with bronchiectasis research 13 (15.9) 13 (16.7) 12 (16.2)
Other (includes a patient, a conference participant, specialist,
potential research participant, former researcher, patient
representative on a committee, member of a steering
committee, a clinician who occasionally identifies patients for
research)
8 (9.8) 7 (9.0) 6 (8.1)
Not disclosed 1 (1.2) 1 (1.3) 1 (1.4)
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the study team (see Figure 3) were included in the
second questionnaire. As such, 32 outcomes were
rated in the second questionnaire. Fifteen of these
outcomes met the criteria for consensus ‘in’ and were
added to the COS. In the third questionnaire, partici-
pants rated the remaining 17 outcomes and three more
outcomes (‘Haemoptysis’, ‘Shortness of breath’ and
‘Activities of daily living’) met the criteria for con-
sensus ‘in’ and were added to the COS. At the end of
three questionnaires, consensus was reached regard-
ing the inclusion of 18 outcomes in the final COS. The
selection and progression of outcomes through the
Delphi exercise is presented in Figure 3. Tables out-
lining how each outcome was rated by participants in
the three questionnaires are provided in Online Sup-
plemental Material.
The final 18 outcomes selected for inclusion in the
COS were ranked in order starting with the highest
proportion of participants rating the outcome as ‘Crit-
ical’ to the lowest proportion as shown in Table 4.
Discussion
This study followed a recommended process for the
development of a COS using a similar approach to the
latest published guidelines.3,5 We avoided the unne-
cessary duplication of research by building upon the
findings of two published studies on outcomes selec-
tion for bronchiectasis trials.9,10 The outcomes iden-
tified by Welsh and colleagues were extracted from
nine high-quality Cochrane systematic reviews and
provided an accurate summary of what previous
researchers measured when investigating interven-
tions for bronchiectasis.5,9 The findings from a con-
sultation with key bronchiectasis stakeholders led to
the inclusion of outcomes in the COS that had been
suggested by participants in the stakeholder panels.10
The Delphi technique is an established method for
reaching consensus in situations where there is some
degree of uncertainty, controversy or incomplete evi-
dence.17 It is currently the method of choice in most
COS development studies.5 This study sought to
involve a range of different stakeholders. Broad con-
sensus is important to COS development to encourage
wide acceptance and implementation.18 Representa-
tion from patients, doctors, nurses and physiothera-
pists was achieved.
Eighteen outcomes were selected to be included in
the COS by the Delphi panel. This was higher than
recently published COSs for other clinical condi-
tions.19–21 There is no recommended maximum num-
ber of outcomes that should be included in a COS. To
collect the amount of data required to measure 18
outcomes would neither be acceptable nor be feasible
in a clinical trial setting. There are different aspects to
the long-term management of bronchiectasis, and
some of the outcomes will be more appropriate than
others for different studies. Investigators may need to
choose outcomes that are of greatest relevance to the
intervention under investigation. However, to pre-
serve a certain degree of homogeneity, selection of
the highest ranking outcomes in the COS, for exam-
ple, outcomes achieving greater than 90% agreement
(see Table 3), would be recommended.
Further attempts to reduce the number of outcomes
in a COS are required. One option would be to con-
duct a face-to-face consensus meeting to allow stake-
holders to deliberate on the suitability of selected
outcomes. The COMET Handbook (version 1.0),5
which was published after this study had been com-
pleted, recommends that stakeholders are given the
opportunity to discuss findings of a Delphi study
before a final COS is agreed. It was not possible to
conduct a face-to-face meeting for this study for
financial reasons, but the planning of such a meeting
would be the next logical step in the development of
Table 4. Final COS ranked in order from the highest to
the lowest proportions of participants rating the outcome
as ‘Critical’.a
Outcome
Participants
(%)
Serious adverse effects 99
Death (disease) 99
Pulmonary exacerbations 97
Admissions to hospital 95
Quality of life 92
Death (all-cause) 90
Adverse effect: shortness of breath 87
Adherence to treatment 87
Sputum characteristics 82
Sputum microbiology 82
Lung function 79
Shortness of breathb 78b
Haemoptysisb 78b
Cough 76
Exercise tolerance 76
Patient perception of health 73
Accident and emergency (A & E)
attendances
72
Activities of daily livingb 74b
COS: core outcome set.
aThe five highest-ranking outcomes are listed in boldface.
bAdded to COS after the third questionnaire.
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the first COS for bronchiectasis. Conducting a ‘vir-
tual’ meeting may also be possible, provided that
there is appropriate technical support and participants
are able to access and feel comfortable using the infra-
structure for such a meeting.
Particular strengths of this study that support the
generalizability of the developed COS were the size
and composition of the Delphi panel. However, this
study did not attempt to recruit participants from the
pharmaceutical industry, who could have provided a
different perspective on the importance of certain out-
comes. The study was limited to European patient
representatives and health professionals, the majority
of whom were based in the United Kingdom, which
may limit the wider generalizability of the results.
A major limitation to this study that restricts the
immediate implementation of the developed COS is
the large number of outcomes yielded from the con-
sensus process. Although the decision to target a
broad scope was deliberate, it is possible that consid-
ering the importance of both pharmacological and
non-pharmacological interventions made it more dif-
ficult for participants to prioritize their ratings, result-
ing in a large number of outcomes reaching
consensus. Limiting the scope of the COS to one type
of intervention may have reduced the number of out-
comes selected. An alternative approach to reducing
the number of outcomes in the COS could have been
to increase the threshold for ‘consensus in’ to limit the
number of outcomes selected for the COS. However,
changing the criteria for consensus after the results
have been analysed would potentially introduce bias
to the process, reducing the reliability of the study.5
The high retention of participants throughout each
stage of the study (approximately 95%) means the
reliability of the results was not substantially compro-
mised by participants dropping out because their
views were not the same of other members.11 The
online distribution of Delphi questionnaires made it
possible to involve a wide variety of participants
across a large geographical area. Use of free survey
software also allowed costs to be minimized. There
was a low time commitment required from partici-
pants, each questionnaire taking around 10 minutes
to complete. A limitation to the remote completion
of questionnaires was that it was difficult to assess
the participants’ comprehension of the task of rating
the importance of outcomes, and therefore, it cannot
be confirmed that the views of the participants were
reliably collected. However, attempts to optimize
participant understanding were made by providing
explanations where needed.
A COS specifies what outcomes should be mea-
sured, rather than how they should be measured. Yet
to fully specify an outcome, information about the
measurement tool and metric used to characterize
results are also required to fulfil the purpose of a
COS.5 The development work described in this article
can be viewed as the first step towards the creation of
an internationally agreed COS and core measurement
set for bronchiectasis. In its current format, it provides
valuable insight into the outcomes of bronchiectasis
that are considered of critical importance to both the
health professionals who are investigating and caring
for people with bronchiectasis and those living with
the condition. Periodic review of the COS and valida-
tion studies will also be required to ensure that the
COS remains relevant and up to date.3
Conclusion
This study has achieved broad consensus from a var-
ied group of stakeholders on the inclusion of 18 out-
comes in a COS for the long-term management of
bronchiectasis. Consideration of at least the five high-
est ranking outcomes could provide the homogeneity
required to better inform clinicians to make evidence-
based decisions. Further research is needed to con-
dense this list of outcomes and to reach consensus
on standardized methods of measuring each outcome
in the agreed COS. This study has provided key
bronchiectasis stakeholders across Europe with the
opportunity to help set the direction for bronchiectasis
research and clinical care.
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